Background Non-steroidal anti-inflammatory drugs (NSAIDs) may be prothrombotic, may worsen hypertension or congestive heart failure and obstruct access to the binding site of aspirin to cyclooxygenase-1 and thereby interfere with aspirin's mechanism of action in reducing death and recurrent myocardial infarction (MI). We hypothesized that treatment with NSAIDs prior to an index MI would be associated with an increase in the risk of death, heart failure and recurrent MI among patients with ST-segment elevation MI (STEMI) treated with fibrinolytic therapy. Methods In ExTRACT-TIMI 25, patients with STEMI were treated with aspirin and fibrinolytic therapy and randomized to either enoxaparin or unfractionated heparin. We included patients who ha...
PURPOSE:There are clinical trial data on risk of acute myocardial infarction (MI) with nonsteroidal ...
Objective To characterise the determinants, time course, and risks of acute myocardial infarction as...
Background: Aspirin is the most widely used antiplatelet drug postmyocardial infarction, yet its opt...
Background: Non steroidal anti-inflammatory drugs (NSAIDs) increase mortality and morbidity after my...
BACKGROUND: Non steroidal anti-inflammatory drugs (NSAIDs) increase mortality and morbidity after my...
Recent clinical trials and observational studies have reported increased coronary events associated ...
Non steroidal anti-inflammatory drugs (NSAIDs) increase mortality and morbidity after myocardial inf...
Recent clinical trials and observational studies have reported increased coronary events associated ...
This editorial refers to ‘NSAIDs are associated with increased risk of atrial fibrillation in patien...
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used drugs, but much attention has been ...
AbstractConclusionThere may be an increased rate of myocardial infarction (MI) in apparently healthy...
AbstractObjectivesThis study was designed to determine if non-aspirin non-steroidal anti-inflammator...
This editorial refers to ‘NSAID use and the risk of hospital-ization for first myocardial infarction...
INTRODUCTION: Use of non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with an incr...
INTRODUCTION AND OBJECTIVES: To investigate how thienopyridine treatment, with or without associated...
PURPOSE:There are clinical trial data on risk of acute myocardial infarction (MI) with nonsteroidal ...
Objective To characterise the determinants, time course, and risks of acute myocardial infarction as...
Background: Aspirin is the most widely used antiplatelet drug postmyocardial infarction, yet its opt...
Background: Non steroidal anti-inflammatory drugs (NSAIDs) increase mortality and morbidity after my...
BACKGROUND: Non steroidal anti-inflammatory drugs (NSAIDs) increase mortality and morbidity after my...
Recent clinical trials and observational studies have reported increased coronary events associated ...
Non steroidal anti-inflammatory drugs (NSAIDs) increase mortality and morbidity after myocardial inf...
Recent clinical trials and observational studies have reported increased coronary events associated ...
This editorial refers to ‘NSAIDs are associated with increased risk of atrial fibrillation in patien...
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used drugs, but much attention has been ...
AbstractConclusionThere may be an increased rate of myocardial infarction (MI) in apparently healthy...
AbstractObjectivesThis study was designed to determine if non-aspirin non-steroidal anti-inflammator...
This editorial refers to ‘NSAID use and the risk of hospital-ization for first myocardial infarction...
INTRODUCTION: Use of non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with an incr...
INTRODUCTION AND OBJECTIVES: To investigate how thienopyridine treatment, with or without associated...
PURPOSE:There are clinical trial data on risk of acute myocardial infarction (MI) with nonsteroidal ...
Objective To characterise the determinants, time course, and risks of acute myocardial infarction as...
Background: Aspirin is the most widely used antiplatelet drug postmyocardial infarction, yet its opt...